BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castilla-lièvre M, Franco D, Gervais P, Kuhnast B, Agostini H, Marthey L, Désarnaud S, Helal B. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:852-9. [DOI: 10.1007/s00259-015-3241-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Reference Citation Analysis]
2 An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, Huang G, Liu J. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging 2022. [PMID: 35147737 DOI: 10.1007/s00259-022-05723-x] [Reference Citation Analysis]
3 Abouzied MM, Fathala A, AlMuhaideb A, Almanea H, Al-Sugair AS, AlSkaff R, Al-Qahtani MH. Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. Radiol Case Rep 2021;16:550-4. [PMID: 33384755 DOI: 10.1016/j.radcr.2020.12.047] [Reference Citation Analysis]
4 Mesguich C, Hulin C, Lascaux A, Bordenave L, Marit G, Hindié E. Choline PET/CT in Multiple Myeloma. Cancers (Basel) 2020;12:E1394. [PMID: 32481661 DOI: 10.3390/cancers12061394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Abrantes AM, Pires AS, Monteiro L, Teixo R, Neves AR, Tavares NT, Marques IA, Botelho MF. Tumour functional imaging by PET. Biochim Biophys Acta Mol Basis Dis 2020;1866:165717. [PMID: 32035103 DOI: 10.1016/j.bbadis.2020.165717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Signore G, Nicod-lalonde M, Prior JO, Bertagna F, Muoio B, Giovanella L, Furlan C, Treglia G. Detection rate of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: an updated systematic review and meta-analysis. Clin Transl Imaging 2019;7:237-53. [DOI: 10.1007/s40336-019-00332-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Horvat N, Monti S, Oliveira BC, Rocha CCT, Giancipoli RG, Mannelli L. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Radiol Oncol. 2018;52:353-364. [PMID: 30511939 DOI: 10.2478/raon-2018-0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
13 Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Review of Medical Devices 2019;16:341-50. [DOI: 10.1080/17434440.2019.1608817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
14 Herrero A, Boivineau L, Cassese G, Assenat E, Riviere B, Faure S, Bedoya JU, Panaro F, Guiu B, Navarro F, Pageaux GP. Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. Transpl Int 2022;35:10412. [PMID: 35401038 DOI: 10.3389/ti.2022.10412] [Reference Citation Analysis]
15 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
16 Tabacchi E, Campana D, Brighi N, Fanti S, Ambrosini V. 68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. Clin Nucl Med 2019;44:238-9. [DOI: 10.1097/rlu.0000000000002426] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun 2021;42:583-91. [PMID: 33625188 DOI: 10.1097/MNM.0000000000001380] [Reference Citation Analysis]
18 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
20 Renzulli M, Brandi N, Argalia G, Brocchi S, Farolfi A, Fanti S, Golfieri R. Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. Radiol Med 2022. [PMID: 35028886 DOI: 10.1007/s11547-022-01449-w] [Reference Citation Analysis]
21 Lanza E, Donadon M, Felisaz P, Mimmo A, Chiti A, Torzilli G, Balzarini L, Lopci E. Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nuclear Medicine Communications 2017;38:826-36. [DOI: 10.1097/mnm.0000000000000719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ferrari C, Di Palo A, Niccoli Asabella A, Didonna V, Ranieri G, Gadaleta CD, Rubini G. 18F-FCH and 90Y PET/CT data for the early evaluation of HCC radioembolisation. Clin Transl Imaging 2018;6:357-67. [DOI: 10.1007/s40336-018-0295-6] [Reference Citation Analysis]
23 Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 2018;101:72-81. [PMID: 29571804 DOI: 10.1016/j.ejrad.2018.01.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 20.0] [Reference Citation Analysis]
24 Lopci E, Fanti S. Non-FDG PET/CT. Recent Results Cancer Res 2020;216:669-718. [PMID: 32594402 DOI: 10.1007/978-3-030-42618-7_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Lu RC, She B, Gao WT, Ji YH, Xu DD, Wang QS, Wang SB. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019; 25(32): 4682-4695 [PMID: 31528094 DOI: 10.3748/wjg.v25.i32.4682] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
26 Aujay G, Debordeaux F, Blanc JF, Lapuyade B, Papadopoulos P, Bordenave L, Trillaud H, Pinaquy JB. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. Nucl Med Commun 2021;42:633-8. [PMID: 33660694 DOI: 10.1097/MNM.0000000000001383] [Reference Citation Analysis]
27 Vogl TJ, Mader C, Michalik S, Hammerstingl R, Koch V. [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting]. Radiologe 2022. [PMID: 35037980 DOI: 10.1007/s00117-021-00965-6] [Reference Citation Analysis]
28 Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:34-39. [PMID: 27775949 DOI: 10.1097/rlu.0000000000001449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
29 Park JH, Kim DH, Kim SH, Kim MY, Baik SK, Hong IS. The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. World J Surg 2018;42:1514-22. [PMID: 29026966 DOI: 10.1007/s00268-017-4275-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Peng R, Zhang Y, Zhao GX, Li J, Shen XZ, Wang JY, Sun JY. Differential regulation of the expression of aquaporins 3 and 9 by Auphen and dbcAMP in the SMMC-7721 hepatocellular carcinoma cell line. Biotech Histochem 2016;91:333-41. [PMID: 27058469 DOI: 10.3109/10520295.2016.1168525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. Journal of Hepatology 2018;69:336-44. [DOI: 10.1016/j.jhep.2018.02.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
32 Ding E, Lu D, Wei L, Feng X, Shen J, Xu W. Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma. Oncol Lett 2020;20:1245-55. [PMID: 32724365 DOI: 10.3892/ol.2020.11681] [Reference Citation Analysis]
33 Tulin PE, Dolgushin MB, Odzharova AA, Mikhaylov AI, Medvedeva BM, Shiryaev SV, Dolgushin BI. Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma. Eur J Hybrid Imaging 2017;1:13. [PMID: 29782602 DOI: 10.1186/s41824-017-0018-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
34 Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am 2018;47:691-714. [PMID: 30115444 DOI: 10.1016/j.gtc.2018.04.011] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Carrion-martin L, Orcajo Rincón J, Rotger A, Gonzalez-leyte M, Márquez Pérez L, Echenagusia M, Matilla A. Radioembolization in liver tumors. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2019;38:370-81. [DOI: 10.1016/j.remnie.2019.06.005] [Reference Citation Analysis]
36 Castello A, Lopci E. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clin Transl Imaging 2020;8:377-92. [DOI: 10.1007/s40336-020-00384-y] [Reference Citation Analysis]
37 Legendre A, Collet G, Lahousse H, Aziz AL, Petyt G. Arterial Phase 18F-Fluorocholine PET/CT in Hepatocellular Carcinoma. Clin Nucl Med 2019;44:133-6. [PMID: 30516677 DOI: 10.1097/RLU.0000000000002397] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Cascales-campos PA, Romero PR, Schneider MA, Lopez-lopez V, Navarro JL, Frutos L, Pons Miñano JA, Paricio PP. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? European Journal of Radiology 2017;91:155-9. [DOI: 10.1016/j.ejrad.2017.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
39 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
40 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
41 Bak-Fredslund KP, Keiding S, Villadsen GE, Kramer S, Schlander S, Sørensen M. [18 F]-Fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma. Liver Int 2020;40:447-55. [PMID: 31705784 DOI: 10.1111/liv.14293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Reizine E, Chalaye J, Mule S, Regnault H, Perrin C, Calderaro J, Laurent A, Amaddeo G, Kobeiter H, Tacher V, Itti E, Luciani A. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol 2021. [PMID: 34494448 DOI: 10.2214/AJR.21.26485] [Reference Citation Analysis]
43 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
44 Sabaté-Llobera A, Mestres-Martí J, Reynés-Llompart G, Lladó L, Mils K, Serrano T, Cortés-Romera M, Bertran E, Fabregat I, Ramos E. 2-[18F]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2554. [PMID: 34070953 DOI: 10.3390/cancers13112554] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]